目的 对2019—2021年天津市人民医院贝伐珠单抗的临床应用情况进行评价，以期促进贝伐珠单抗超说明书用药的管理及其临床合理应用。方法 回顾性分析天津市人民医院2019年1月—2021年12月使用贝伐珠单抗患者的用药信息，根据说明书及指南评价其应用的合理性。结果 共收集1 313例患者（6 134次医嘱），通过适应症、治疗方案、用法用量3个方面评价应用合理性。结果 显示，存在适应症不适宜情况占比0.07%，用法用量不适宜情况占比4.77%，其中包括给药浓度不适宜（1.21%）、给药途径不适宜（0.23%）、与手术间隔时间不适宜（3.33%）。结论 天津市人民医院贝伐珠单抗的临床应用基本符合国内外说明书及指南要求，但也存在一定的超说明书用药情况。医院及临床药师应持续规范抗肿瘤药物超说明书使用的管理，促进抗肿瘤药物的合理应用。

Objective To evaluate the clinical application of bevacizumab in Tianjin Union Medical Center from 2019 to 2021, in order to promote the management of off-label use of bevacizumab and its rational clinical application. Methods The medication information of patients receiving bevacizumab from January 2019 to December 2021 in Tianjin Union Medical Center was retrospectively analyzed, and the rationality of its application was evaluated according to the instructions and guidelines. Results A total of 1 313 patients (6 134 times of medical advice) were collected to evaluate the rationality of application in three aspects:indication, treatment plan, usage and dosage. The results showed that unsuitable indications accounted for 0.07%, unsuitable usage and dosage accounted for 4.77%, including unsuitable concentration (1.21%), unsuitable route of administration (0.23%), and unsuitable interval time with operation (3.33%). Conclusion The clinical application of bevacizumab in Tianjin Union Medical Center basically met the requirements of domestic and foreign instructions and guidelines, but there were some cases of off-label drug use. Hospitals and clinical pharmacists should continue to standardize the management of off-label use of antineoplastic drugs to promote rational use of antineoplastic drugs.

R979.1